-
Anderson LJ, Tong S, 2010: Update on SARS research and other possibly zoonotic coronaviruses[J]. Int J Antimicrob Agents, 36, S21-25.
-
Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S, 1997: Selection and identification of single domain antibody fragments from camel heavy-chain antibodies[J]. FEBS Lett, 414, 521-526. doi: 10.1016/S0014-5793(97)01062-4
-
Chen Z, Zhang L, Qin C, Ba L, Yi CE, Zhang F, Wei Q, He T, Yu W, Yu J, Gao H, Tu X, Gettie A, Farzan M, Yuen KY, Ho DD, 2005: Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region[J]. J Virol, 79, 2678-2688. doi: 10.1128/JVI.79.5.2678-2688.2005
-
Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G, 2005: Use of convalescent plasma therapy in SARS patients in Hong Kong[J]. Eur J Clin Microbiol Infect Dis, 24, 44-46. doi: 10.1007/s10096-004-1271-9
-
Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S, 2009: The spike protein of SARS-CoV-a target for vaccine and therapeutic development[J]. Nat Rev Microbiol, 7, 226-236. doi: 10.1038/nrmicro2090
-
Ebrahimizadeh W, Mousavi Gargari S, Rajabibazl M, Safaee Ardekani L, Zare H, Bakherad H, 2013: Isolation and characterization of protective anti-LPS nanobody against V[J]. cholerae O1 recognizing Inaba and Ogawa serotypes. Appl Microbiol Biotechnol, 97, 4457-4466.
-
Frenken LGJ, van der Linden RHJ, Hermans PWJJ, Bos JW, Ruuls RC, de Geus B, Verrips CT, 2000: Isolation of antigen specific Llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae[J]. J Biotechnol, 78, 11-21. doi: 10.1016/S0168-1656(99)00228-X
-
Gallagher TM, Buchmeier MJ, 2001: Coronavirus spike proteins in viral entry and pathogenesis[J]. Virology, 279, 371-374. doi: 10.1006/viro.2000.0757
-
Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM, 2005: Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice[J]. J Infect Dis, 191, 507-514. doi: 10.1086/427242
-
Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R, 1993: Naturally occurring antibodies devoid of light chains[J]. Nature, 363, 446-448. doi: 10.1038/363446a0
-
Han DP, Kim HG, Kim YB, Poon LL, Cho MW, 2004: Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein[J]. Virology, 326, 140-149. doi: 10.1016/j.virol.2004.05.017
-
He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S, 2004: Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine[J]. Biochem Biophys Res Commun, 324, 773-781. doi: 10.1016/j.bbrc.2004.09.106
-
Hu J, Gao Q, He C, Huang A, Tang N, Wang K, 2020: Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2[J]. Genes Dis, 7, 551-557. doi: 10.1016/j.gendis.2020.07.006
-
Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ, Group SW, 2003: A novel coronavirus associated with severe acute respiratory syndrome[J]. N Engl J Med, 348, 1953-1966. doi: 10.1056/NEJMoa030781
-
Kuiken T, Fouchier RAM, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, Laman JD, de Jong T, van Doornu G, Lim W, Ling AE, Chan PKS, Tam JS, Zambon MC, Gopal R, Drosten C, van der Werf S, Escriou N, Manuguerra J-C, Stöhr K, Peiris JSM, Osterhaus ADME, 2003: Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome[J]. Lancet, 362, 263-270. doi: 10.1016/S0140-6736(03)13967-0
-
Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, De Genst E, Wyns L, Muyldermans S, 1998: Potent enzyme inhibitors derived from dromedary heavy-chain antibodies[J]. EMBO J, 17, 3512-3520. doi: 10.1093/emboj/17.13.3512
-
Li F, 2013: Receptor recognition and cross-species infections of SARS coronavirus[J]. Antiviral Res, 100, 246-254. doi: 10.1016/j.antiviral.2013.08.014
-
Li F, Li W, Farzan M, Harrison SC, 2005: Structure of SARS coronavirus spike receptor-binding domain complexed with receptor[J]. Science, 309, 1864-1868. doi: 10.1126/science.1116480
-
Liang G, Chen Q, Xu J, Liu Y, Lim W, Peiris JS, Anderson LJ, Ruan L, Li H, Kan B, Di B, Cheng P, Chan KH, Erdman DD, Gu S, Yan X, Liang W, Zhou D, Haynes L, Duan S, Zhang X, Zheng H, Gao Y, Tong S, Li D, Fang L, Qin P, Xu W, Group SDW, 2004: Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China[J]. Emerg Infect Dis, 10, 1774-1781. doi: 10.3201/eid1010.040445
-
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y, Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W, Tan W, 2020: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 395, 565-574. doi: 10.1016/S0140-6736(20)30251-8
-
Mir MA, Mehraj U, Sheikh BA, Hamdani SS, 2020: Nanobodies: the "magic bullets" in therapeutics, drug delivery and diagnostics[J]. Hum Antibodies, 28, 29-51. doi: 10.3233/HAB-190390
-
Pearson H, Clarke T, Abbott A, Knight J, Cyranoski D, 2003: SARS: what have we learned?[J]. Nature, 424, 121-126. doi: 10.1038/424121a
-
Peiris JS, Yuen KY, Osterhaus AD, Stohr K, 2003: The severe acute respiratory syndrome[J]. N Engl J Med, 349, 2431-2441. doi: 10.1056/NEJMra032498
-
Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, Dimitrov DS, 2006: Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody[J]. J Biol Chem, 281, 15829-15836. doi: 10.1074/jbc.M600697200
-
Roberts A, Thomas WD, Guarner J, Lamirande EW, Babcock GJ, Greenough TC, Vogel L, Hayes N, Sullivan JL, Zaki S, Subbarao K, Ambrosino DM, 2006: Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters[J]. J Infect Dis, 193, 685-692. doi: 10.1086/500143
-
Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK, Investigators H, 2019: Caplacizumab treatment for acquired thrombotic thrombocytopenic Purpura[J]. N Engl J Med, 380, 335-346. doi: 10.1056/NEJMoa1806311
-
Subbarao K, McAuliffe J, Vogel L, Fahle G, Fischer S, Tatti K, Packard M, Shieh WJ, Zaki S, Murphy B, 2004: Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice[J]. J Virol, 78, 3572-3577. doi: 10.1128/JVI.78.7.3572-3577.2004
-
Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallarico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, Marasco WA, 2004: Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association[J]. Proc Natl Acad Sci USA, 101, 2536-2541. doi: 10.1073/pnas.0307140101
-
Sui J, Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M, Marasco WA, 2005: Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants[J]. J Virol, 79, 5900-5906. doi: 10.1128/JVI.79.10.5900-5906.2005
-
Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A, 2004: An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus[J]. Nat Med, 10, 871-875. doi: 10.1038/nm1080
-
Tsunetsugu-Yokota Y, Ohnishi K, Takemori T, 2006: Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine[J]. Rev Med Virol, 16, 117-131. doi: 10.1002/rmv.492
-
Wang W, Hou X, Yang X, Liu A, Tang Z, Mo F, Yin S, Lu X, 2019: Highly sensitive detection of CTLA-4-positive T-cell subgroups based on nanobody and fluorescent carbon quantum dots[J]. Oncol Lett, 18, 109-116.
-
Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA, 2012: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia[J]. N Engl J Med, 367, 1814-1820. doi: 10.1056/NEJMoa1211721
-
Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, Wang L, Yu F, Zheng BJ, Jiang S, Zhou Y, 2013: A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV[J]. Virol J, 10, 266-. doi: 10.1186/1743-422X-10-266
-
Zhao G, He L, Sun S, Qiu H, Tai W, Chen J, Li J, Chen Y, Guo Y, Wang Y, Shang J, Ji K, Fan R, Du E, Jiang S, Li F, Du L, Zhou Y, 2018: A novel nanobody targeting middle east respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV[J]. J Virol, 92, e00837-e918.